Journal of Nepal Medical Association, 2021 Introduction: Sputum non-conversion is smear positive tuberculosis despite anti-tubercular therapy. Various factors may lead to sputum non-conversion including resistance to anti-tubercular drugs, age, gender, disease severity, non-compliance, drugs ...
Naveen Prakash Shah +5 more
doaj +1 more source
Synthesis, in-vitro antitubercular, antifungal activities and in silico molecular docking study of Chalcone derivatives from 1-(2'-Hydroxyphenyl)-3-(substituted-phenyl)-2-propenone. [PDF]
Microbes and Infectious Diseases, 2023 Background: Â Tuberculosis (TB) is one of the major global health problems and faced to the increased resistance of Mycobacterium tuberculosis strains against existing antitubercular agents, it is important to look for new antitubercular drugs.
Arnold Mulula +4 more
doaj +1 more source
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
, 2022 Hepatology, EarlyView.
Robert J. Fontana +6 more
wiley +1 more source
Isoniazid associated psychosis: case series from a tertiary care centre
Open Journal of Psychiatry and Allied Sciences, 2018 Isoniazid (INH) is a commonly used first line antitubercular drug. INH associated psychosis is a rare psychiatric manifestation. We report two cases of pulmonary tuberculosis, where the patients developed psychosis after being given a therapeutic dose of
Hemendra Singh +3 more
doaj +1 more source
Clinically Relevant Interactions between Atypical Antipsychotics and Anti-Infective Agents
Pharmaceuticals, 2020 This is a comprehensive review of the literature on drug interactions (DIs) between atypical antipsychotics and anti-infective agents that focuses on those DIs with the potential to be clinically relevant and classifies them as pharmacokinetic (PK) or ...
Edoardo Spina +3 more
doaj +1 more source
Inhalable fucoidan microparticles combining two antitubercular drugs with potential application in pulmonary tuberculosis therapy [PDF]
, 2018 The pulmonary delivery of antitubercular drugs is a promising approach to treat lung tuberculosis. This strategy not only allows targeting the infected organ instantly, it can also reduce the systemic adverse effects of the antibiotics. In light of that,
Ana Grenha +7 more
core +2 more sources
Pathogens, 2018 Mycobacterium tuberculosis is the causative agent of tuberculosis, an ancient disease which, still today, represents a major threat for the world population. Despite the advances in medicine and the development of effective antitubercular drugs, the cure
Davide M. Ferraris +3 more
doaj +1 more source
Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis. [PDF]
PLoS ONE, 2014 The reductively activated nitroaromatic class of antimicrobials, which include nitroimidazole and the more metabolically labile nitrofuran antitubercular agents, have demonstrated some potential for development as therapeutics against dormant TB bacilli.
Rakesh +12 more
doaj +1 more source
Journal of Dr. NTR University of Health Sciences, 2021 Anti-tubercular therapy (ATT) drugs are the mainstay of management of tuberculosis worldwide. These medicines are used extensively across the globe in treating tubercular infections of any organ.
Simarjit S Rehsi +6 more
doaj +1 more source
Structural Simplification of Bedaquiline: the Discovery of 3-(4-(N,N-dimethylaminomethyl)phenyl)quinoline Derived Antitubercular Lead Compounds [PDF]
, 2016 Bedaquiline (BDQ) is a novel and highly potent last-line antituberculosis drug that was approved by the US FDA in 2013. Owing to its stereo-structural complexity, chemical synthesis and compound optimization are rather difficult and expensive. This study
Cui, HC +8 more
core +1 more source